| 000 | 01727 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517151229.0 | ||
| 264 | 0 | _c20180212 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a2050-084X | ||
| 024 | 7 |
_a10.7554/eLife.17137 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Hui Qin | |
| 245 | 0 | 0 |
_aCombined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human _h[electronic resource] |
| 260 |
_beLife _c04 2017 |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnaplastic Lymphoma Kinase |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aHeterografts |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 | _aNeoplasm Transplantation |
| 650 | 0 | 4 |
_aNeuroblastoma _xdrug therapy |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-mdm2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 |
_aReceptor Protein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSulfones _xpharmacology |
| 700 | 1 | _aHalilovic, Ensar | |
| 700 | 1 | _aLi, Xiaoyan | |
| 700 | 1 | _aLiang, Jinsheng | |
| 700 | 1 | _aCao, Yichen | |
| 700 | 1 | _aRakiec, Daniel P | |
| 700 | 1 | _aRuddy, David A | |
| 700 | 1 | _aJeay, Sebastien | |
| 700 | 1 | _aWuerthner, Jens U | |
| 700 | 1 | _aTimple, Noelito | |
| 700 | 1 | _aKasibhatla, Shailaja | |
| 700 | 1 | _aLi, Nanxin | |
| 700 | 1 | _aWilliams, Juliet A | |
| 700 | 1 | _aSellers, William R | |
| 700 | 1 | _aHuang, Alan | |
| 700 | 1 | _aLi, Fang | |
| 773 | 0 |
_teLife _gvol. 6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.7554/eLife.17137 _zAvailable from publisher's website |
| 999 |
_c27096830 _d27096830 |
||